Skip to content

Exploring Ketamine’s Expanding Roles Beyond Anesthesia, Including PTSD, Chronic Pain, and Depression Treatment

Jawad Hameed, Roheena Wadud

Pakistan Journal of Medical and Health Sciences December 28, 2023 DOI: 10.53350/pjmhs020231712310 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective observational study Peer reviewed
Sample size 70
Population Patients receiving ketamine treatment at Anesthesia Department, Lady Reading Hospital-MTI Peshawar, Pakistan
Intervention Ketamine
Duration January, 2023 to June, 2023
Topics Depression Ketamine Esketamine PTSD
Keywords Chronic pain Depression economics Adverse effect Anesthesia Cognition
Key findings 78.5% of patients had positive responses with no adverse effects, and symptom severity was significantly reduced following ketamine treatment.

Abstract

Introduction: Ketamine, traditionally known for its anesthetic properties, is now being explored for its rapid-acting therapeutic effects in various psychiatric and pain-related disorders. Its emerging role in managing treatment-resistant depression (TRD), chronic pain, and post-traumatic stress disorder (PTSD) is supported by recent clinical evidence.

Objective: To evaluate the effectiveness of ketamine in the treatment of chronic pain, TRD, and PTSD among patients in a tertiary care setting. Materials and

Method: This retrospective observational study was conducted at Anesthesia Department, Lady Reading Hospital-MTI Peshawar, Pakistan, from January, 2023 to June, 2023. Based on the predetermined inclusion and exclusion criteria, 70 records for patients receiving ketamine treatment were assessed. Clinical outcomes were assessed using standardized rating scales for pain, depression, and PTSD.

Results: Substantial healing occurred for each condition, and symptom severity was significantly reduced following ketamine treatment. Overall, 78.5% of patients had positive responses with no adverse effects.

Conclusion: Ketamine represents a viable and fast-acting alternative treatment for patients with refractory psychiatric conditions and pain. Keywords: Ketamine, depression, PTSD, chronic pain, treatment-resistant, rapid-acting therapy, NMDA antagonist.

Comparable studies

Other observational and cohort studies on ketamine for PTSD, most cited first.

Study Year Design Participants
Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Outpatients with treatment-resistant depression and PTSD 2018 Retrospective review n = 37
Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study. Adults with a history of major depressive disorder, generalized anxiety disorder, or... 2024 Retrospective effectiveness study n = 346
Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample. Help-seeking individuals with depression and/or PTSD 2025 Observational cohort n = 624
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm. Outpatients with elevated PTSD Checklist for DSM-5 scores 2025 Retrospective study n = 117
Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging Individuals with major depressive disorder or posttraumatic stress disorder 2024 Observational cohort n = 20

Explore topics

By condition and practice